What if you could relieve knee pain not by transplanting cells, but by injecting the liquid they were grown in? A Japanese research team tried exactly that. Five of seven patients improved, and no serious side effects were reported. It is a genuinely new idea for a problem 375 million people live with. It is also a seven-patient study with no control group, and reading it properly means understanding what that does and does not allow you to say.

The Big Idea: Not the Cells, Their Broth

At the 25th Annual Meeting of the Japanese Society for Regenerative Medicine, held in Kobe on March 19–20, 2026, a collaborative team from four institutions unveiled results that could reshape the future of knee osteoarthritis treatment.

The team, comprising Mirise iPS Clinic (Tokyo), Showa Medical University Fujigaoka Hospital's orthopedic department, Nippon Medical School's plastic surgery and regenerative medicine division, and iPEACE Inc. (headquartered in Palo Alto, California, with a subsidiary in Kyoto), presented findings from what may be the world's first clinical study injecting iPS cell-derived "conditioned medium" directly into arthritic knees.

So what exactly is this conditioned medium (iPSC-CM)? When iPS cells, the Nobel Prize-winning stem cells invented in Japan, are grown in culture, they release a cocktail of bioactive molecules into the surrounding liquid. These include anti-inflammatory factors and cartilage-protective compounds. The research team collected this nutrient-rich liquid, purified it to pharmaceutical-grade (GMP) standards, and injected it straight into patients' knee joints. Think of it as harvesting the "healing essence" that iPS cells naturally produce, without transplanting the cells themselves.

This approach represents a fundamentally different philosophy from conventional iPS cell therapy. Traditional regenerative medicine involves transforming iPS cells into specific cell types (like cartilage cells or nerve cells) and transplanting them into the body. The conditioned medium approach skips the cells entirely, which theoretically lowers the risk of tumor formation and simplifies manufacturing.

How to Read Seven Patients and Twelve Knees

The study enrolled seven patients (12 knees total) with knee osteoarthritis. Their average age was 70.1 years, with five women and two men. The severity ranged from moderate to severe, as classified by the Kellgren-Lawrence grading system (Grades 2–4).

The results were striking. Using the internationally recognized OMERACT-OARSI responder criteria, a gold standard for measuring improvement in osteoarthritis studies, 71.4% of patients (5 out of 7) and 66.7% of knees (8 out of 12) were classified as "responders," meaning they showed meaningful improvement.

On the safety front, the results were equally remarkable: zero infections, zero increased pain, zero swelling, zero bleeding, and no serious adverse events whatsoever. Over six months of follow-up, improvement was observed across all five domains of the KOOS (Knee injury and Osteoarthritis Outcome Score): pain, symptoms, daily activities, sports and recreation, and quality of life.

According to the research team's review of published literature, no prior clinical report exists of iPSC-derived conditioned medium being injected into human knees for osteoarthritis, making this potentially the first such study in the world.

Reading that number requires some care. This was a single-arm study of seven patients with no placebo control. Injections into the knee joint are an area where saline alone produces reported improvement in more than half of patients across multiple trials. So of that 71.4%, how much is the conditioned medium and how much is the injection itself is not something this study can answer.

The same applies to safety. No serious adverse events in seven people is encouraging, but seven cases cannot detect an event that occurs once in several hundred. "No side effects were observed" and "there are no side effects" are different statements.

The work was also presented at a conference rather than published in a peer-reviewed journal, and the presenting group includes a clinic that offers this treatment. Both are worth holding in mind.

Why Knee Osteoarthritis?

Knee osteoarthritis (knee OA) occurs when the cartilage cushioning the knee joint wears down over time, causing pain, stiffness, and reduced mobility. It's driven primarily by aging, obesity, and repetitive joint stress.

The scale of the problem is enormous. In Japan alone, an estimated 25 million people suffer from knee OA, nearly one in five of the entire population. Globally, the 2021 Global Burden of Disease Study estimated approximately 375 million prevalent cases of knee OA, with projections showing continued growth as populations age and obesity rates climb. Osteoarthritis as a whole affects over 600 million people worldwide, with the knee being the most commonly affected joint.

Current treatments range from hyaluronic acid injections and anti-inflammatory medications to, as a last resort, total knee replacement surgery, a major operation costing roughly $30,000–$50,000 in the United States. For millions of patients whose symptoms don't respond to conservative treatments but who aren't yet candidates for (or can't access) surgery, there has been a frustrating treatment gap. This study offers a potential new option to fill that gap.

Japan's iPS Cell Legacy

The foundation of this research traces directly back to Professor Shinya Yamanaka at Kyoto University, who in 2006 became the first person to create iPS cells (induced pluripotent stem cells), an achievement that earned him the Nobel Prize in Physiology or Medicine in 2012. Since then, Japan has maintained a global leadership position in bringing iPS cell technology from the lab to the bedside.

On March 6, 2026, Sumitomo Pharma's "Amshepuri" (generic name raguneprocel), an allogeneic iPS-derived dopaminergic progenitor cell product for Parkinson's disease, received conditional and time-limited approval from Japan's health ministry, a world first for an iPS-derived regenerative medicine product. Insurance coverage followed in May at a price of ¥55.3 million. Even that product, though, is at the stage of gathering data from roughly 35 patients across seven sites within a seven-year window to seek full approval. The evidence is still being built.

Other Japanese clinical trials are advancing in spinal cord injury, retinal disease, heart failure, and blood disorders.

The conditioned medium approach adds an entirely new dimension to this expanding toolkit. Instead of asking "What cells can we make from iPS cells?" it asks "What beneficial substances do iPS cells produce?", a paradigm shift that could make iPS-derived therapies more accessible and affordable.

The Team, From Tokyo to Silicon Valley

The study exemplifies Japan's "sangaku-i renkei" (industry-academia-medicine collaboration) model. Clinical expertise came from Mirise iPS Clinic, led by Dr. Daisuke Tomita, and Showa Medical University's Dr. Atsushi Sato. Academic research support was provided by Nippon Medical School's Dr. Mohamed Abdelhakim. And iPEACE Inc., led by CEO Koji Tanabe and headquartered in Palo Alto with operations in Kyoto, brought biotech manufacturing expertise from Silicon Valley.

Dr. Tomita described the preliminary data as providing "strong evidence to advance to the next stage," highlighting the combination of zero adverse events, over 71% improvement, and sustained effects at six months.

Where Conditioned Medium Sits in the Regulations

This part matters. Conditioned medium therapy is not an approved medicine.

On July 31, 2024, Japan's Ministry of Health, Labour and Welfare issued a notice to regenerative medicine providers stating plainly that for treatments using human stem cell conditioned medium and exosomes, there is no medicine anywhere, Japan or overseas, that has demonstrated efficacy and safety and obtained regulatory approval. Providers must therefore proceed under their own responsibility with particular attention to safety.

Because conditioned medium contains no cells, it also falls outside the "processed cell product" framework of Japan's Act on the Safety of Regenerative Medicine. In December 2024, a health ministry council raised the question of whether extracellular vesicles including conditioned medium should be regulated on par with processed cell products. That review is ongoing.

In Japan, a considerable number of clinics offer conditioned medium injections privately, for cosmetic or joint indications. That is precisely why a study like this one matters: it is an attempt to bring evidence into a field that largely lacks it. Which also means most conditioned medium treatment currently on offer has no data of this kind behind it.

What Needs to Happen Next

Promising as these results are, important limitations exist. The study included only seven patients with no placebo control group, meaning the observed improvements cannot yet be definitively attributed to the treatment rather than placebo effects or natural fluctuation. The research team has outlined the following next steps: conducting larger controlled studies with placebo comparison, investigating the biological mechanisms through which the conditioned medium acts, and systematically accumulating long-term safety and efficacy data.

These are standard steps in the long journey from preliminary findings to approved treatment. But the combination of meaningful improvement, excellent safety, and a novel mechanism makes this a study worth watching closely.

How Does Your Country Treat Knee Pain?

Japan's approach to knee osteoarthritis is evolving rapidly, with regenerative medicine joining the treatment toolkit alongside traditional options. This conditioned medium study hints at a future where "cell-free regenerative medicine" could become a new category entirely, potentially simpler, cheaper, and more widely available than cell transplantation.

In an aging world where knee pain affects hundreds of millions, new treatment options matter enormously. What's knee treatment like in your country? Is regenerative medicine available, or is joint replacement still the main surgical option? How much does knee surgery cost? We'd love to hear about the knee care landscape where you live, share your experience!

References